The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.
 
Andrew David Knight
No Relationships to Disclose
 
Lilit Karapetyan
No Relationships to Disclose
 
Sabrina Bruno
Stock and Other Ownership Interests - Abbott Laboratories (I); AstraZeneca (I); Atea (I); CVS Health (I); Gilead Sciences (I); Intercept Pharmaceuticals (I); Merck (I); Moderna Therapeutics; Moderna Therapeutics (I)
 
Hassan Mohammed Abushukair
No Relationships to Disclose
 
Na Bo
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Cindy Sander
No Relationships to Disclose
 
John M. M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Magnolia Innovation; Merck; Natera; OncoCyte; OncoSec; PATHAI; Pfizer; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron